Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 5, 2013, Pages 510-517

  Amirkhosravi, Ali ^a   Bigsby, Glenn ^b   Desai, Hina ^a   Rivera Amaya, Mildred ^a   Coll, Enriqueta ^a   Robles Carrillo, Liza ^a   Faust, Patricia ^b   Waters, Alane ^a   Meyer, Todd ^a   Reyes, Enriquo ^a   Langer, Florian ^c   Francis, John L ^a  

^a FLORIDA HOSPITAL   (United States)

^b FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

CA 125; D dimer; ovarian cancer; thromboelastography; tissue factor

Indexed keywords

CA 125 ANTIGEN; D DIMER; THROMBOPLASTIN;

ADULT; AGED; ARTICLE; BLOOD; BLOOD CLOTTING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PILOT STUDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBIN TIME; THROMBOELASTOGRAPHY;

ADULT; AGED; BLOOD COAGULATION; CA-125 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HEMOSTASIS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PREOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY; THROMBELASTOGRAPHY; THROMBOPLASTIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84879952099     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32835e63b7     Document Type: Article

References (23)

1. Im SS, Gordon AN, Buttin BM, Leath CA 3rd, Gostout BS, Shah C, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005; 105:35-41.
2. Dearking AC, Aletti GD, Mc Gree ME, Weaver AL, Sommerfield MK, Cliby WA. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol 2007; 110:841-848.
3. Chan JK, Kapp DS, Shin JY, Husain A, Teng NN, Berek JS, et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol 2007; 109:1342-1350.
4. Suh KS, Park SW, Castro A, Patel H, Blake P, Liang M, Goy A. Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Rev Mol Diagn 2010; 10:1069-1083.
5. Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M. Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax. Eur Respir J 2008; 31:140-142.
6. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past andthefuture. Int JBiol Markers 1998; 13:179-187.
7. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, Farias-Eisner R. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 2008; 199:215-223.
8. Khoo SK, Rylatt DB, Parsons P, Wilson K, Webb MJ, Dickie G, et al. Serial D-dimer levels in the assessment of tumor mass and clinical outcome in ovarian cancer. Gynecol Oncol 1988; 29:188-198.
9. Gadducci A, Baicchi U, Marrai R, Ferdeghini M, Bianchi R, Facchini V. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 1996; 60:197-202.
10. Uno K, Homma S, Satoh T, Nakanishi K, Abe D, Matsumoto K, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 2007; 29:290-295.
11. Rao LV. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992; 11:249-266.
12. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004; 50:187-196.
13. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85:967-972.
14. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105:1734-1741.
15. Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008; 6:1517-1524.
16. Han LY, Landen CN Jr, Kamat AA, Lopez A, Bender DP, Mueller P, et al. Preoperative serum tissue factor levels are an independent prognostic factor in patientswith ovarian carcinoma.JClin Oncol 2006; 24:755-761.
17. Hemker HC, Giessen P, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: monitoring thrombin generation for the analysis of platelet-rich-plasma. Thromb Haemost 2000; 83:583-591.
18. Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992; 18:104-116.
19. Von Tempelhoff G, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997; 77:456-461.
20. Gadducci A, Marrai R, Baicchi U, Ferdeghini M, Fanucchi A, Weiss C, Genazzani AR. Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer. Gynecol Oncol 1997; 66:85-88.
21. Uno K, Homma S, Satoh T, Nakanishi K, Abe D, Matsumoto K, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 2007; 96:290-295.
22. Versteeg HH, Ruf W. Thiol pathways in the regulation of tissue factor prothrombotic activity. Curr Opin Hematol 2011; 18:343-348.
23. Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation; Which? Where? When? Arterioscler Thromb Vasc Biol 2009; 29:1989-1996.